Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Cellular senescence predicts treatment outcome in metastasised colorectal cancer

Open access

Abstract

BACKGROUND: Cellular senescence is a terminal cell-cycle arrest that occurs in response to activated oncogenes and DNA-damaging chemotherapy. Whether cancer cell senescence at diagnosis might be predictive for treatment outcome is unknown. METHODS: A senescence index (SI) was developed and used to retrospectively correlate the treatment outcome of 30 UICC stage IV colorectal cancer (CRC) patients with their SI at diagnosis. RESULTS: 5-Fluorouracil/leucovorin-treated CRC patients achieved a significantly longer progression-free survival when presenting with SI-positive tumours before therapy (median 12.0 vs 6.0 months; P=0.044). CONCLUSION: Cancer cell senescence predicts treatment outcome in metastasised CRC. Prospective analyses of larger patient cohorts are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6605784

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Stratification of stage IV CRC samples by a senescence index (SI) predicts PFS to first-line 5-FU/LV therapy. (A) Proportions of senescent cases in cryo-preserved colorectal tissue sections of the indicated groups (normal crypt mucosa (n=5, 0 senescent); adenoma (n=12, 8 senescent), invasive carcinoma (n=6, 1 senescent)). Note that 9 out of 12 adenoma and 2 out of 6 carcinoma cases would score ‘senescent’ if judged in low-proliferating areas only (see D). (B) Average frequency of senescent cells per group (as in A), measured as the percentage of SA-β-gal-positive (blue) cells, and compared to the rate of Ki67-positive (red nuclear staining) cells (top: error bars represent the standard deviation; bottom: matched areas of representative photomicrographs – a non-senescent normal crypt mucosa, a senescent adenoma and a formally non-senescent carcinoma (but showing numerous senescent cells)). Notably, in normal colorectal mucosa, only cells of the most differentiated luminal mucosa stain SA-β-gal-positive. (C) FFPE sections of pelleted Ras-infected senescent (sen.) human fibroblasts (SA-β-gal-positive and Ki67-negative frozen material as a reference) show much stronger immunoreactivity for p-ERK, HP1γ and cytoplasmic PAI-1 when compared with non-senescent (non-sen.) mock-infected fibroblasts. (D) SI values, based on the expression of these three markers, were obtained in 30 cases of stage IV CRC specimens at diagnosis, and used to stratify PFS following 5-FU/LV first-line chemotherapy (senescent (n=12; blue line) vs non-senescent (n=17; red line); one case scored ‘not conclusive’ (see Figure 2B)). Genomic sequencing in a subset of these 29 specimens identified K-Ras codon 12 or 13 mutations in 5 out of 6 senescent, but only 2 out of 11 non-senescent cases (inset). Note that a primary stratification by the K-Ras mutation status unveiled no significant differences in PFS (P=0.128).
Figure 1 Stratification of stage IV CRC samples by a senescence index (SI) predicts PFS to first-line 5-FU/LV therapy. (A) Proportions of senescent cases in cryo-preserved colorectal tissue sections of the indicated groups (normal crypt mucosa (n=5, 0 senescent); adenoma (n=12, 8 senescent), invasive carcinoma (n=6, 1 senescent)). Note that 9 out of 12 adenoma and 2 out of 6 carcinoma cases would score ‘senescent’ if judged in low-proliferating areas only (see D). (B) Average frequency of senescent cells per group (as in A), measured as the percentage of SA-β-gal-positive (blue) cells, and compared to the rate of Ki67-positive (red nuclear staining) cells (top: error bars represent the standard deviation; bottom: matched areas of representative photomicrographs – a non-senescent normal crypt mucosa, a senescent adenoma and a formally non-senescent carcinoma (but showing numerous senescent cells)). Notably, in normal colorectal mucosa, only cells of the most differentiated luminal mucosa stain SA-β-gal-positive. (C) FFPE sections of pelleted Ras-infected senescent (sen.) human fibroblasts (SA-β-gal-positive and Ki67-negative frozen material as a reference) show much stronger immunoreactivity for p-ERK, HP1γ and cytoplasmic PAI-1 when compared with non-senescent (non-sen.) mock-infected fibroblasts. (D) SI values, based on the expression of these three markers, were obtained in 30 cases of stage IV CRC specimens at diagnosis, and used to stratify PFS following 5-FU/LV first-line chemotherapy (senescent (n=12; blue line) vs non-senescent (n=17; red line); one case scored ‘not conclusive’ (see Figure 2B)). Genomic sequencing in a subset of these 29 specimens identified K-Ras codon 12 or 13 mutations in 5 out of 6 senescent, but only 2 out of 11 non-senescent cases (inset). Note that a primary stratification by the K-Ras mutation status unveiled no significant differences in PFS (P=0.128).CC BY · PubMed Central
Figure 2 Generation and validation of the senescence index (SI). (A) Technical flow diagram of the generation and application of the SI in a Ras-transduced human fibroblast cell line and in colorectal tissue specimens. (B) Formula and cut-off values of the SI based on the expression p-ERK, HP1γ and PAI-1. Coefficients reflect the reciprocal average percentage of cells that stained positive for the respective marker in the learning adenomas to normalise the relative weight of the three markers. The correction value –19 was chosen to set the discrimination threshold at 0, with the range between −1 and +1 considered ‘non-conclusive’. (C) The majority of validation set adenomas is senescent when analysed by the SI. A set of seven matched samples (frozen and FFPE material from the same adenoma) underscores the high concordance between the SA-β-gal/Ki67- (see definition in Materials and Methods section) and the SI-based assignment.
Figure 2 Generation and validation of the senescence index (SI). (A) Technical flow diagram of the generation and application of the SI in a Ras-transduced human fibroblast cell line and in colorectal tissue specimens. (B) Formula and cut-off values of the SI based on the expression p-ERK, HP1γ and PAI-1. Coefficients reflect the reciprocal average percentage of cells that stained positive for the respective marker in the learning adenomas to normalise the relative weight of the three markers. The correction value –19 was chosen to set the discrimination threshold at 0, with the range between −1 and +1 considered ‘non-conclusive’. (C) The majority of validation set adenomas is senescent when analysed by the SI. A set of seven matched samples (frozen and FFPE material from the same adenoma) underscores the high concordance between the SA-β-gal/Ki67- (see definition in Materials and Methods section) and the SI-based assignment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 121

Metadata

Authors
Haugstetter, A. M., Loddenkemper, C., Lenze, D., Gröne, J., Standfuß, C., Petersen, I., Dörken, B., & Schmitt, C. A.
Affiliations
  • Stiftung Charité (DE)
  • Technical University of Munich (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • Freie Universität Berlin (DE)
  • Friedrich Schiller University Jena (DE)
  • Max Delbrück Center (DE)
Corresponding author
Schmitt, C A
Venue
British Journal of Cancer
Published
2010-07-13
Volume
103
Issue
4
Pages
505-509
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2049256375
Cited by
117
References
28
Citations by year
2026: 2 · 2025: 9 · 2024: 11 · 2023: 16 · 2022: 8 · 2021: 11 · 2020: 9 · 2019: 4 · 2018: 8 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 5 · 2013: 4 · 2012: 7
FWCI
3.68
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
Deutsche Krebshilfe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
cellular senescence, colorectal cancer, metastatic colorectal cancer, treatment outcome prediction, 5-fluorouracil, leucovorin, progression-free survival, cell cycle arrest
MeSH terms
Leucovorin, Fluorouracil, Humans, Predictive Value of Tests, Prognosis, Colorectal Neoplasms, Treatment Outcome, Cellular Senescence, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cellular senescence predicts treatment outcome in metastasised colorectal cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6605784
The paper
Haugstetter, A. M., Loddenkemper, C., Lenze, D., Gröne, J., Standfuß, C., Petersen, I., Dörken, B., & Schmitt, C. A. (2010). Cellular senescence predicts treatment outcome in metastasised colorectal cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605784

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.